The clinical effect of the inhibitor of apopotosis protein livin in melanoma

Itay Lazar, Riki Perlman, Michal Lotem, Tamar Peretz, Dina Ben-Yehuda*, Luna Kadouri

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Objective: The inhibitor of apoptosis protein (IAP) livin is frequently overexpressed in melanoma. Livin binds caspases and thereby inhibits apoptosis. We found that caspases cleave livin to produce a truncated form with a paradoxical proapoptotic activity. Methods: We assessed the correlation of livin expression with survival among 114 melanoma patients treated with an autologous melanoma vaccine. In 52 patients, resection resulted in no evidence of disease (NED) and 62 remained with active disease (WAD). Protein levels were assessed using Western blot. Results: We found livin protein expression in 44/114 samples (38.4%). Median overall survival was 1.4 years in NED patients with high levels of livin protein, 8.4 years in those with low-intermediate levels and not reached in patients who did not express livin (p = 0.025). The corresponding overall survival was 2.3 years among WAD patients with high levels of livin protein, 11.3 years in those with low-intermediate levels and, paradoxically, only 4.0 years in patients who did not express livin (p = 0.012). Conclusion: Livin protein expression may play a role in the progression of melanoma and correlates with survival. A high level of the protein is associated with a poor prognosis. However, in WAD patients low to intermediate level of livin, rather than absence of the protein, is associated with a favorable prognosis. This is probably due to the paradoxical proapoptotic activity of this important regulator of apoptosis.

Original languageAmerican English
Pages (from-to)197-204
Number of pages8
JournalOncology
Volume82
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Keywords

  • Inhibitor of apoptosis protein
  • Livin
  • Melanoma
  • Survival

Fingerprint

Dive into the research topics of 'The clinical effect of the inhibitor of apopotosis protein livin in melanoma'. Together they form a unique fingerprint.

Cite this